AmBisome liposomal amphotericin B data

An independent university researcher presented a pharmacoeconomic analysis based on data from two Phase III safety and efficacy studies of AmBisome at the European Bone Marrow Transplant Society meeting.

Compared to amphotericin B, first-line treatment with AmBisome is more effective in treating febrile, immunocompromised neutropenic adults with presumed invasive fungal infections, but also more expensive. ...